ALBANY, N.Y., Aug. 30, 2016 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2016 at 3:30 p.m. ET. A live audio webcast of the presentation can be accessed at AMRI's Investor Relations web site at http://ir.amriglobal.com/events.cfm?CalendarID=2.
The webcast will be archived for 90 days following the live presentation.
About AMRIAlbany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product Manufacturing (DPM), and Fine Chemicals. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent and cytotoxic compounds, controlled substances, steroids, hormones, and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
Advertisement
The webcast will be archived for 90 days following the live presentation.
About AMRIAlbany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product Manufacturing (DPM), and Fine Chemicals. Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent and cytotoxic compounds, controlled substances, steroids, hormones, and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amri-ceo-to-present-at-morgan-stanley-global-healthcare-conference-300319352.html
SOURCE AMRI
